The results confirmed that PDCL3 had high efficiency in distinguishing tumors from normal samples in BRCA, COAD, GBM, HNSC, LIHC, LUAD, LUSC, STAD, and THYM, with upregulation of PDCL3 expression correlating with poor prognosis in ACC, BRCA, GBM, HNSC, KIRP, LGG, LIHC, LUAD, MESO, STAD, UCEC, and UVM. This evidence concerns the gene PDCL3 and glioblastoma.